FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vaccine patents



      
           
This page is updated frequently with new Vaccine-related patent applications. Subscribe to the Vaccine RSS feed to automatically get the update: related Vaccine RSS feeds. RSS updates for this page: Vaccine RSS RSS


Neisseria meningitidis antigens and compositions

Engen Bio

Influenza vaccine and therapy

Date/App# patent app List of recent Vaccine-related patents
03/26/15
20150087807
 Lipopolysaccharide-targeted peptide mimic vaccine against q fever patent thumbnailnew patent Lipopolysaccharide-targeted peptide mimic vaccine against q fever
A vaccine and method of vaccination for conferring immunity to q fever is described. The vaccine comprises a polypeptide with a sequence of sltwhkhelhrk (m1e41920) or sppwhkhelhrk (m1e44), or at least 90% identity to m1e41920 or m1e44.
03/26/15
20150086592
 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections patent thumbnailnew patent Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs.
Sequoia Sciences, Inc
03/26/15
20150086591
 Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections patent thumbnailnew patent Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs.
Sequoia Sciences, Inc
03/26/15
20150086588
 Parainfluenza virus 5 based vaccines patent thumbnailnew patent Parainfluenza virus 5 based vaccines
The present invention provides safe, stable, efficacious, and cost-effective vaccines based on viral expression vectors that include a parainfluenza virus 5 (piv5) genome including a heterologous nucleotide sequence expressing a heterologous polypeptide. In some embodiments, the heterologous nucleotide sequence is inserted closer to the leader than between the hemagglutinin-neuroaminidase (hn) gene and the large rna polymerase protein (l) gene of the piv5 genome.
University Of Georgia Research Foundation, Inc.
03/26/15
20150086587
 Vaccine adjuvant patent thumbnailnew patent Vaccine adjuvant
Oil-based adjuvant emulsions, immunogenic compositions, and methods of using the same to elicit immunological responses in a subject are provided. The oil-based adjuvants comprise a plant-derived surfactant, such as gum arabic, an aqueous component, and an oil.
University Of Tennessee Research Foundation
03/26/15
20150086585
 Triterpene saponins, methods of synthesis and uses thereof patent thumbnailnew patent Triterpene saponins, methods of synthesis and uses thereof
The present invention relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, intermediates thereto, and uses thereof. Qs-7 is a potent immuno-adjuvant that is significantly less toxic than qs-21, a related saponin that is currently the favored adjuvant in anticancer and antiviral vaccines.
Memorial Sloan-kettering Institute For Cancer Research
03/26/15
20150086582
 Neisseria meningitidis antigens and compositions patent thumbnailnew patent Neisseria meningitidis antigens and compositions
The invention provides proteins from neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics..
J. Craig Venter Institute, Inc.
03/26/15
20150086581
 Fast diagnosis and personalized treatment for acne patent thumbnailnew patent Fast diagnosis and personalized treatment for acne
Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses rt4, rt5, rt7, rt8, rt9, or rt10. Methods for treating acne include administering an effective amount of a drug specifically targeting rt4, rt5, rt7, rt8, rt9, or rt10, such as small molecules, antisense molecules, sirnas, biologics, antibodies, phages, vaccines, or combination thereof..
The Regents Of The University Of California
03/26/15
20150086578
 Human cytomegalovirus vaccine patent thumbnailnew patent Human cytomegalovirus vaccine
Combination peptides, polypeptides and proteins that elicit high titer neutralizing antibodies against cytomegalovirus (cmv) are provided. The combination peptides, polypeptides and proteins encompass epitopes located within the ul130 and ul131 components of the gh/gl/ul128-131 protein complex, in particular, epitopes located within amino acid residues 27-46 of ul130 and amino acid residues 90-106 of ul131.
Virginia Commonwealth University
03/26/15
20150086560
 Influenza vaccine and therapy patent thumbnailnew patent Influenza vaccine and therapy
The present invention is directed generally to m1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-m1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-m1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response..
Engen Bio Inc.
03/19/15
20150079132

Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly


This disclosure is directed to compositions that combine the polysaccharide-specific antibody protection afforded by the conventional vaccines through carrier effects provided by one or more pneumococcal common t-cell antigen(s) together with streptococcus pneumoniae-specific th-17 responses elicited by the pneumococcal carrier common t-cell antigen. The disclosed compositions are useful for pan-serotypic protection against np carriage, and antibody responses against common pneumococcal virulence factors, potentially useful for pan-serotype protection against streptococcus pneumoniae invasive diseases..
Path
03/19/15
20150079129

Vaccine


The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein d from h.
Glaxosmithkline Biologicals S.a.
03/19/15
20150079127

Canine babesiosis vaccine antigen


The present invention relates to the field of veterinary parasitology, especially of canine babesiosis. In particular the invention relates to a polypeptide being a novel canine babesia antigen (cba), or fragments thereof, and to compositions comprising this antigen, to nucleic acids encoding the antigen, antibodies against the antigen, and medical uses of this antigen, fragments, antibodies, or encoding nucleic acids.
Intervet Inc.
03/19/15
20150079125

Vaccine


The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular, the present invention relates to bacterial polysaccharides conjugated to protein d from h.
Glaxosmithkline Biologicals S.a.
03/19/15
20150079124

Neisseria meningitidis antigens and compositions


The invention provides proteins from neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics..
J. Craig Venter Institute, Inc.
03/19/15
20150079122

Human rotavirus vaccine strains and diagnostics


A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains cdc-9 and cdc-66, fragments thereof, homologues thereof, or combinations thereof.
The United States Of America As Represented By The Secretary Of The Dept. Of Health & Human Se
03/19/15
20150079121

Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same


Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode an rsv immunogen are disclosed. Nucleic acid are disclosed that comprise the sequences that encodes consensus rsv f protein or immunogenic fragment thereof, sequences that encodes an rsv g(a) protein or immunogenic fragment thereof and sequences that encodes an rsv g(b) protein or immunogenic fragment thereof.
The Trustees Of The University Of Pennsylvania
03/19/15
20150079119

Identification and use of novopeptides for the treatment of cancer


Compositions, methods, systems, apparatus and/or articles of manufacture are disclosed for reducing the susceptibility of a population and/or members thereof to cancer, which may include anti-cancer vaccines, components thereof which may include novopeptides, and methods relating thereto.. .
03/19/15
20150079034

Compositions comprising angiogenic factors and methods of use thereof


The present invention provides recombinant listeria strains comprising an angiogenic factor, recombinant polypeptides comprising an angiogenic factor operatively linked to a polypeptide comprising a pest-like sequence, recombinant nucleotide molecules encoding same, related vaccines, and immunogenic and therapeutic methods utilizing same.. .
The Trustees Of The University Of Pennsylvania
03/12/15
20150072929

Pharmaceutical composition comprising a mixture of carboxylated oligopeptides


A pharmaceutical composition comprising a mixture of carboxylated oligopeptides, derived by hydrolysis of eukaryotic or prokaryotic cells and their subsequent partial carboxylation through acylation or alkylation of the amino acid and basic amino acid residues in the amino terminal structure of the oligopeptides. The resulting pharmaceutical composition can be used in production of medical drugs effective in the treatment of cancer, pancreatitis, viral infection, for the development of vaccines..
03/12/15
20150072354

Compounds and methods for diagnosis and treatment of leishmaniasis


Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more leishmania antigens, or a variant thereof.
Infectious Disease Research Institute
03/12/15
20150072016

Microparticles with adsorbed polynucleotide-containing species


Microparticles with adsorbed polynucleotide-containing species, compositions containing the same, methods of making such microparticles, and uses thereof are disclosed. The microparticles comprise (a) a biodegradable polymer, such as a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, or a polycyanoacrylate, (b) a cationic surfactant such as cetyltrimethylammonium bromide, (c) and a polynucleotide-containing species adsorbed on the surface of the microparticles, wherein the polynucleotide-containing species constitutes at least 5 percent of the total weight of said microparticles.
Novartis Vaccines And Diagnostics, Inc.
03/12/15
20150072007

Therapeutic stem cell composition and stimulant, facilitator, accelerator, and synergizer thereof, growth factor, anti-inflammatory composition and uses thereof


The present invention relates to a non-invasive medical therapy and a composition for avoiding organ transplantation, or controlling biological rejection of transplanted organs, or treating organs under consideration for replacement by transplant, and otherwise treating aged, diseased and/or abnormal tissues and/or organs. More specifically, the non-invasive medical therapy involves administering to a patient an elemental nutritional feeding comprising a free amino acid profile simulating and/or replicating a targeted diseased or transplanted tissue and/or organ.
Immunopath Profile, Inc.
03/12/15
20150071994

Gastrointestinal site-specific oral vaccination forumulations active on the ileum and appendix


The invention provides oral vaccine formulations which deliver an antigen in the vicinity of the distal ileum and the area of the ileal brake and/or the appendix. These vaccines are useful in the treatment and/or prevention of variety of disorders, including viral and bacterial infections and cancers.
Therabiome, Llc
03/12/15
20150071990

Method of treating patients with a mucinous glycoprotein (muc-1) vaccine


The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a muc-1-based formulation. The formulation may be a muc-1 based liposomal vaccine formulation..
Oncothyreon Inc.
03/12/15
20150071964

Methods and compositions for viral vectored vaccines


Methods and compositions are provided herein for non-invasive administration of an adenoviral vector (ad-vector) vaccine with an adjuvant, such as a tlr3 agonist. These methods provide, for example, an increase in the immune response to the vaccine, an increase in the immunogenicity of the ad-vector vaccine, an antigen sparing effect and improved safety with an effective protective immune response to the vaccine..
Vaxin Inc.
03/12/15
20150071961

Siderophore conjugate immunogenic compositions and vaccines


An immunogenic composition comprising a siderophore covalently linked to a pharmaceutically acceptable carrier molecule wherein the antigenicity of the siderophore moiety is sufficient to stimulate an immunologic response to the siderophore when the composition is circulating in the bloodstream of a human or non-human animal and vaccine.. .
University Of Florida Research Foundation, Inc.
03/12/15
20150071956

Novel surface exposed haemophilus influenzae protein (protein e; pe)


The present invention relates to a surface exposed protein (protein e, pe), a virnlence factor, which can be detected in haemophilus influenzae, having an amino acid sequence as described in seq id no 1, an immunogenic fragment of said surface exposed protein, and a recombinant immunogenic protein (pe (a)) or truncated variants thereof based on said surface exposed protein. Nucleic acid sequences, vaccines, plasmids and phages, non human hosts, recombinant nucleic acid sequences, fusion proteins and fusion products are also described.
03/12/15
20150071927

Anti-her2 and anti-igf-ir bi-specific antibodies and uses thereof


Disclosed are antibodies, or binding fragments thereof, that specifically bind to human her2 and human igf-ir. Also provided are nucleic acid molecules encoding the disclosed antibodies and binding fragments and vectors and host cells containing these nucleic acid molecules.
The University Of Hong Kong
03/05/15
20150065692

Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies


The present invention provides a method for inducing a cancer specific immune response against muc1 using an immunogenic glycopeptide. Other aspects of the invention are a pharmaceutical composition comprising the immunogenic glycopeptide and a cancer vaccine comprising the immunogenic glycopeptide.
Cancer Research Technology Limited
03/05/15
20150064240

Muc1 based glycolipopeptide vaccine with adjuvant


Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.. .
Oncothyreon Inc.
03/05/15
20150064217

Pluripotent germ layer origin antigen presenting cancer vaccine


The disclosure provides reagents, methods, and kits, for treating or preventing cancers derived from each of the germ layers (endoderm, mesoderm, ectoderm, neural crest). The reagent encompasses interferon-gamma (ifn-gamma) responsive cancer cells, where the cells are autophagic and non-apoptotic cancer cells, and where the cells express mhc class ii..
California Stem Cell, Inc.
03/05/15
20150064216

Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants


vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsrna together with an anti-influenza vaccine.. .
Hemispherx Biopharma, Inc.
03/05/15
20150064215

Therapeutic delivery and expression system, methods and uses thereof


Therapeutic methods for cancer treatments using a combined prokaryotic-eukaryotic delivery and expression system for the delivery of multiple therapeutic factors via a modified tumor-targeted bacteria. A targeted bacteria-vector system elicits an inter-kingdom dual expression (ikde) of antitumor agents, in the nucleus or cytoplasm of eukaryotic cells, with priming and maintenance of the vector in the bacterium.
The University Of Hong Kong
03/05/15
20150064214

Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses


A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.. .
The Usa, As Represented By The Secretary, Department Of Health & Human Services
02/26/15
20150056636

Transgenic immunodeficient mouse expressing human sirp-alpha


The present invention provides a transgenic mouse which comprises a deficiency for murine t lymphocytes, b lymphocytes and nk cells, a deficiency for murine mhc class i and mhc class ii molecules, and a functional xenogenic sirpα transgene. This mouse is useful for in vivo screening of various compounds, including immuno-therapeutic agents and vaccines.
Institut Pasteur
02/26/15
20150056254

Method for manufacturing transdermally delivered hyaluronic acid-protein conjugate and transdermally delivered hyaluronic acid-protein conjugate manufactured using same


A transdermal delivery system of drug and a method of preparing the same are provided. More specifically, the invention can be a transdermal delivery system applied for various protein drugs such as vaccines and chemical drugs, because the drug delivery system has a biocompatibility, biodegradation property, transdermal delivery property, the safety of human body, maximum activity of protein drugs, good bio-conjugation efficiency and a long-term efficacy, a method of preparing the same and its use..
Phi Biomed Co., Ltd.
02/26/15
20150056249

Influenza vaccines


The present invention relates to influenza vaccine compositions and vaccination schemes for immunizing against influenza disease, in particular it relates to immunogenic compositions comprising an antigen or a antigenic preparation from a first influenza virus strain and an oil-in-water emulsion adjuvant for use in inducing a immune response against at least one second influenza virus strain wherein said second influenza virus strain is from a different type or from a different subtype than said first influenza virus strain.. .
Glaxosmithkline Biologicals, Sa
02/26/15
20150056247

Sequential and repeated immunization with four or more vector-based hiv gene vaccines


The present invention provides a combined aids vaccine for preventing and/or treating aids, which consists of four or more different vector-based aids vaccines, wherein hiv protein gene comprised in the different aids vaccines may be same. A use method of the vaccine comprises inoculation of one aids vaccine each time, wherein inoculation of each vaccine may be continuously performed twice, and after sequential application of the four or more vector vaccines, repeated sequential application of the vector vaccines may be performed.
Beijing University Of Technology
02/26/15
20150056244

Antigens and vaccines directed against human enteroviruses


The instant invention provides materials and methods for producing immunologically active antigens derived from members of the picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection.
Sentinext Therapeutics Sdn Bhd
02/26/15
20150056243

Multicomponent or monocomponent vaccine to be used against chagas disease, pharmaceutical compositions containing them, procedure for the obtention of immunogen of said vaccines, and nucleic acid used in said procedure


A vaccine against the chagas disease, capable of stimulating the immune response against the trans-sialidase virulence factor of the trypanosoma cruzi parasite, which is a multicomponent vaccine comprising: (a) an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of thereof and (b) one or more polynucleotides including the regions codifying one or more immunogenic polypeptides, or a monocomponent vaccine comprising at least one component selected among an immunogenic portion formed by one or more recombinant or synthetic polypeptides or fractions of them and a group of polynucleotides including the regions codifying one or more immunogenic polypeptides derived from trypanosoma cruzi and pharmaceutical compositions containing said multicomponent and monocomponent vaccines, the procedures for obtaining the immunogen portion of said vaccines and the nucleic acid used in the procedure.. .
02/26/15
20150056239

Fused antigen vaccines and compositions against streptococcus pneumoniae


Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in streptococcus pneumoniae that contain fusion proteins.
Children's Medical Center Corporation
02/26/15
20150056237

Method of altering the immundominance hierarchy of hiv gag by dna vaccine expressing conserved regions


The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus..
University Of Washington
02/26/15
20150056236

An infectious cdna clone of north american porcine reproductive and respiratory syndrome (prrs) virus and uses thereof


The invention provides isolated polynucleotide molecules that comprise a dna sequence encoding an infectious rna sequence encoding a genetically-modified north american prrs virus, wherein the polynucleotide molecule lacks at least one detectable antigenic epitope of north american prrs virus. The invention also provides vaccines comprising genetically modified north american prrs virus, rna molecules, plasmids and viral vectors comprising the isolated polynucleotide molecules.
Zoetis Llc
02/26/15
20150056234

Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines


The present invention relates to novel cd4+ and cd8+ t cell epitopes that are specific for hpv-specific e6 and e7 oncoproteins, to peptides comprising these novel t cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of hpv related diseases. Preferred epitopes are recognized by a t cell that infiltrates a cervical neoplastic lesion or by a t cell from a draining lymph node, and are presented by an hla-dq or hla-dp molecule, or an hla-b..
Academisch Ziekenhuis Leiden H.o.d.n. Lumc
02/26/15
20150056231

Recombinant papaya mosaic virus coat proteins and uses thereof in influenza vaccines


Recombinant papaya mosaic virus (papmv) coat proteins comprising one or more antigenic peptides derived from an influenza virus antigen, such as from the m2e peptide, fused at a position within a predicted random coil within 13 amino acids of the n-terminus of the coat protein, uses thereof to prepare virus-like particles (vlps), and uses of the vlps in influenza vaccines.. .
Folia Biotech Inc.
02/26/15
20150056230

Equine encephalitis virus vaccines and methods of using thereof


Disclosed herein are nucleotide sequences which encode a plurality of structural proteins, except the capsid, of an equine encephalitis virus, wherein the nucleotide sequence is codon-optimized for mammalian expression. The nucleotide sequences are codon-optimized for expression in humans.
02/26/15
20150056228

Methods and materials for generating t cells


The document provides to methods and materials for generating t cells (e.g., antigen-specific cd4+ t cells). For example, methods and materials for using nested mhc class ii epitopes as vaccines to generate activated cd4+ t cells in vivo or as reagents to generate activated cd4+ t cells ex vivo are provided..
Mayo Foundation For Medical Education And Research
02/26/15
20150056209

Peptide mimotopes to oxidation specific epitopes


Provided herein are peptide mimotopes that are useful for generating antibodies and in the preparation of vaccines and diagnostics for treating and diagnosing coronary artery disease.. .
Medizinsche Universitat Wien
02/26/15
20150056197

Vaccines against hpv


The present invention relates to therapeutic compounds, such as vaccines against human papillomavirus (hpv) and in particular to dna vaccines against hpv16 or hpv18. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a dna vaccine or used separately.
Vaccibody As


Popular terms: [SEARCH]



Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vaccine for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vaccine with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         













0.3793

3544

2 - 1 - 77